Literature DB >> 15324599

Memantine approved to treat moderate to severe Alzheimer's disease.

Karen Marder.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324599     DOI: 10.1007/s11910-004-0080-y

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  4 in total

Review 1.  Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.

Authors:  Stuart A Lipton
Journal:  NeuroRx       Date:  2004-01

2.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 3.  The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

Authors:  P Murali Doraiswamy
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

4.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

  4 in total
  1 in total

Review 1.  Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease.

Authors:  T Heinen-Kammerer; H Rulhoff; S Nelles; R Rychlik
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.